|Articles|October 1, 2003
Raptiva rounds hot corner, heads for hotter market
Austin, Texas - Genentech's Raptiva took a significant step toward approval by the U.S. Food and Drug Administration. The psoriasis treatment received a unanimous recommendation from an FDA advisory panel.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Next-Generation IL-4Rα Targeting and Potential Dermatologic Implications
2
Recludix Pharma’s REX-8756 for Type 2 Inflammatory Diseases Enters First Human Trials
3
Alpha Tau Submits First PMA Module to FDA for Novel cSCC Treatment, Alpha DaRT
4
Oruka Reports Positive Interim Phase 1 Data for ORKA-002, Advances ORKA-001
5














